Activated Protein C Resistance in the Absence of Factor V Leiden Mutation is Associated with an Increased Risk of Thrombotic Complications in Patients with Multiple Myeloma Receiving First-Line Thalidomide-Dexamethasone Therapy
Presented by:
Journal of the Hellenic Society of Haematology (HAEMA) / Abderrahman Abdelkefi, Neila Ben Romdhane, Mohamed Younes and Sami Guermazi
Summary points:
Two patients with deep vein thrombosis following treatment with thalidomide are presented. These cases review patient presentation, and management.
Activated Protein C Resistance in the Absence of Factor V Leiden Mutation is Associated with an Increased Risk of Thrombotic Complications in Patients with Multiple Myeloma Receiving First-Line Thalidomide-Dexamethasone Therapy
